NVAX
Novavax·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 3
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
Significant Net Income Decline
EPS Below Expectations
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About NVAX
Novavax, Inc.
A world's leading COVID-19 vaccine development company
700 Quince Orchard Road, Gaithersburg, Maryland 20878
--
Novavax, Inc., incorporated in 1987 under the laws of the State of Delaware, is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The company's vaccine technology platform is based on proprietary recombinant nanoparticle vaccine technology including virus-like particles (VLP) and protein nanoparticle vaccine candidates. The company's vaccine candidate is a genetically engineered three-dimensional nanostructure that contains immunologically important proteins. The company's vaccine product pipeline targets a variety of infectious diseases, and drug candidates are currently in clinical development for respiratory syncytial virus (RSV), seasonal influenza, and pandemic influenza. In addition, the company's joint venture in India, CPL Biologics Private Limited (CPLB), is actively developing a number of vaccine candidates that have been genetically engineered by Novavax.
Earnings Call
Q1/2025
Estimate EPS0.71
Actual EPS2.93
Estimate Revenue343.85M
Actual Revenue667.00M
Novavax's Q1 2025 Earnings Call: Unraveling Contradictions in FDA Pathways, Partnerships, and Clinical Trials
May 19,2025 08:35
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS-0.11
Actual EPS0.62
Estimate Revenue165.01M
Actual Revenue239.00M
Novavax's 2025 Q2 Earnings Call: Navigating Key Contradictions in CIC Strategy and Regulatory Pathways
Aug 13,2025 01:45
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
NVAX has released its 2025 Q3 earnings. EPS was reported at -1.25, versus the expected -0.92, missing expectations. The chart below visualizes how NVAX has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
NVAX has released its 2025 Q3 earnings report, with revenue of 70.44M, reflecting a YoY change of -16.64%, and net profit of -202.38M, showing a YoY change of -66.84%. The Sankey diagram below clearly presents NVAX's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
